BGB-283 Deemed Effective in Phase I Study.
In a phase I trial, BGB-283, which targets the RAF family of proteins, was found to be safe and tolerable-and effective-in treating patients with a variety of solid tumors harboring mutations in BRAF, KRAS, and NRAS.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D015507:Drugs, Investigational; D020558:GTP Phosphohydrolases / Q000235:genetics; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D009154:Mutation; D009287:Naphthyridines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C000609386:BGB-283; D001562:Benzimidazoles; D015507:Drugs, Investigational; C117307:KRAS protein, human; D008565:Membrane Proteins; D009287:Naphthyridines; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020558:GTP Phosphohydrolases; C579846:NRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)